BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 32988960)

  • 21. Clinicopathological significance of ataxia telangiectasia-mutated (ATM) kinase and ataxia telangiectasia-mutated and Rad3-related (ATR) kinase in MYC overexpressed breast cancers.
    Savva C; De Souza K; Ali R; Rakha EA; Green AR; Madhusudan S
    Breast Cancer Res Treat; 2019 May; 175(1):105-115. PubMed ID: 30746633
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The development of ataxia telangiectasia mutated kinase inhibitors.
    Andrs M; Korabecny J; Nepovimova E; Jun D; Hodny Z; Moravcova S; Hanzlikova H; Kuca K
    Mini Rev Med Chem; 2014; 14(10):805-11. PubMed ID: 25138084
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The antiproliferative effects of ataxia-telangiectasia mutated and ATM- and Rad3-related inhibitions and their enhancements with the cytotoxicity of DNA damaging agents in cholangiocarcinoma cells.
    Moolmuang B; Ruchirawat M
    J Pharm Pharmacol; 2021 Mar; 73(1):40-51. PubMed ID: 33791808
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma.
    Shi Q; Shen LY; Dong B; Fu H; Kang XZ; Yang YB; Dai L; Yan WP; Xiong HC; Liang Z; Chen KN
    Cancer Lett; 2018 Sep; 432():56-68. PubMed ID: 29890208
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer.
    Kwon M; Kim G; Kim R; Kim KT; Kim ST; Smith S; Mortimer PGS; Hong JY; Loembé AB; Irurzun-Arana I; Koulai L; Kim KM; Kang WK; Dean E; Park WY; Lee J
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35790315
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations).
    Mahdi H; Hafez N; Doroshow D; Sohal D; Keedy V; Do KT; LoRusso P; Jürgensmeier J; Avedissian M; Sklar J; Glover C; Felicetti B; Dean E; Mortimer P; Shapiro GI; Eder JP
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34527850
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rational Design of 5-(4-(Isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine (VX-970, M6620): Optimization of Intra- and Intermolecular Polar Interactions of a New Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase Inhibitor.
    Knegtel R; Charrier JD; Durrant S; Davis C; O'Donnell M; Storck P; MacCormick S; Kay D; Pinder J; Virani A; Twin H; Griffiths M; Reaper P; Littlewood P; Young S; Golec J; Pollard J
    J Med Chem; 2019 Jun; 62(11):5547-5561. PubMed ID: 31074988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand.
    Mei L; Zhang J; He K; Zhang J
    J Hematol Oncol; 2019 Apr; 12(1):43. PubMed ID: 31018854
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer Models.
    Wengner AM; Siemeister G; Lücking U; Lefranc J; Wortmann L; Lienau P; Bader B; Bömer U; Moosmayer D; Eberspächer U; Golfier S; Schatz CA; Baumgart SJ; Haendler B; Lejeune P; Schlicker A; von Nussbaum F; Brands M; Ziegelbauer K; Mumberg D
    Mol Cancer Ther; 2020 Jan; 19(1):26-38. PubMed ID: 31582533
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dbf4 is direct downstream target of ataxia telangiectasia mutated (ATM) and ataxia telangiectasia and Rad3-related (ATR) protein to regulate intra-S-phase checkpoint.
    Lee AY; Chiba T; Truong LN; Cheng AN; Do J; Cho MJ; Chen L; Wu X
    J Biol Chem; 2012 Jan; 287(4):2531-43. PubMed ID: 22123827
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Investigation of switch from ATM to ATR signaling at the sites of DNA damage induced by low and high LET radiation.
    Saha J; Wang M; Cucinotta FA
    DNA Repair (Amst); 2013 Dec; 12(12):1143-51. PubMed ID: 24238855
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ATM loss disrupts the autophagy-lysosomal pathway.
    Cheng A; Tse KH; Chow HM; Gan Y; Song X; Ma F; Qian YXY; She W; Herrup K
    Autophagy; 2021 Aug; 17(8):1998-2010. PubMed ID: 32757690
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Contribution of ATM and ATR to the resistance of glioblastoma and malignant melanoma cells to the methylating anticancer drug temozolomide.
    Eich M; Roos WP; Nikolova T; Kaina B
    Mol Cancer Ther; 2013 Nov; 12(11):2529-40. PubMed ID: 23960094
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disease severity in a mouse model of ataxia telangiectasia is modulated by the DNA damage checkpoint gene Hus1.
    Balmus G; Zhu M; Mukherjee S; Lyndaker AM; Hume KR; Lee J; Riccio ML; Reeves AP; Sutter NB; Noden DM; Peters RM; Weiss RS
    Hum Mol Genet; 2012 Aug; 21(15):3408-20. PubMed ID: 22575700
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer.
    Zhou Y; Börcsök J; Adib E; Kamran SC; Neil AJ; Stawiski K; Freeman D; Stormoen DR; Sztupinszki Z; Samant A; Nassar A; Bekele RT; Hanlon T; Valentine H; Epstein I; Sharma B; Felt K; Abbosh P; Wu CL; Efstathiou JA; Miyamoto DT; Anderson W; Szallasi Z; Mouw KW
    Sci Adv; 2023 Nov; 9(47):eadg2263. PubMed ID: 37992168
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A proteomic analysis of ataxia telangiectasia-mutated (ATM)/ATM-Rad3-related (ATR) substrates identifies the ubiquitin-proteasome system as a regulator for DNA damage checkpoints.
    Mu JJ; Wang Y; Luo H; Leng M; Zhang J; Yang T; Besusso D; Jung SY; Qin J
    J Biol Chem; 2007 Jun; 282(24):17330-4. PubMed ID: 17478428
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The ATM and Rad3-Related (ATR) Protein Kinase Pathway Is Activated by Herpes Simplex Virus 1 and Required for Efficient Viral Replication.
    Edwards TG; Bloom DC; Fisher C
    J Virol; 2018 Mar; 92(6):. PubMed ID: 29263259
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation.
    Dillon MT; Guevara J; Mohammed K; Patin EC; Smith SA; Dean E; Jones GN; Willis SE; Petrone M; Silva C; Thway K; Bunce C; Roxanis I; Nenclares P; Wilkins A; McLaughlin M; Jayme-Laiche A; Benafif S; Nintos G; Kwatra V; Grove L; Mansfield D; Proszek P; Martin P; Moore L; Swales KE; Banerji U; Saunders MP; Spicer J; Forster MD; Harrington KJ
    J Clin Invest; 2024 Jan; 134(2):. PubMed ID: 37934611
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sensors and Inhibitors for the Detection of Ataxia Telangiectasia Mutated (ATM) Protein Kinase.
    Huang C; Filippone NR; Reiner T; Roberts S
    Mol Pharm; 2021 Jul; 18(7):2470-2481. PubMed ID: 34125542
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Specific Human ATR and ATM Inhibitors Modulate Single Strand DNA Formation in
    da Silva RB; Bertoldo WDR; Naves LL; de Vito FB; Damasceno JD; Tosi LRO; Machado CR; Pedrosa AL
    Front Cell Infect Microbiol; 2021; 11():802613. PubMed ID: 35059327
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.